2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Warts
1
Virus Diseases
1
Skin Diseases, Viral
1
Skin Diseases, Infectious
1
Skin Diseases
1
Sexually Transmitted Diseases, Viral
1
Sexually Transmitted Diseases
1
Papillomavirus Infections
1
Condylomata Acuminata
1
Interventions
Cisplatin
1514
Carboplatin
1416
Cyclophosphamide
1359
Gemcitabine
1235
Bevacizumab
1223
Paclitaxel
1210
Radiotherapy
1173
Docetaxel
1079
pembrolizumab
1026
Oxaliplatin
934
Capecitabine
898
Fluorouracil
832
Rituximab
729
Doxorubicin
683
Nivolumab
679
Dexamethasone
665
Etoposide
660
Irinotecan
622
Leucovorin
574
Pemetrexed
508
Drug Therapy
491
Cetuximab
481
Trastuzumab
467
Cytarabine
466
Magnetic Resonance Spectroscopy
457
Filgrastim
446
Prednisone
432
Lenalidomide
409
Specimen Handling
407
Temozolomide
400
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
VP-102
×
Clear all
NCT03981822
2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2
Completed
105 enrolled
24 charts